Cabco TR Bellsth Debs TR Certs (BFH.L) Quote

Thanks for all the info Kiwi. Been a long busy day so I will have to do some more DD on this one but it appears to be promising. The fact that the drug does not have the ejection fraction problem is important in my books. This could be another CYTK.

Hopefully - the biggest negative variable in congressional foolery is the awareness of the people that will vote them out.

Years back, when I was selling omega-3, I would sometimes have customers come in and say that their doc might not want them to take fish oils because of the bleeding risk. I would tell them that they should tell the doctor if he thinks they are such a great anti-coagulant, that he should take them

You gotta be kidding --- baby boomers in the targeted demographic...

At this rate stick a fork in SMCE

Flat out lie but nice try

Smart one's are loading up some cheapies, loaded more today, know what you own, ignore any negatively they are here because they need to tell us all how bad Nsav is, that in itself is a strong buy signal, ignore the shills, know what you own, do not reply to the paid monkey's they want your bananas.

Good quotes, Janet, I am learning from you!

Employee Spotlight: Karl Littau CTO | Sakuu

Our CTO Karl Littau's journey from academia to industry giants like Applied Materials and Xerox PARC has equipped him with a deep understanding of manufacturing challenges and opportunities. Now, at Sakuu, he's building dry-process printin

Pause the vdeo at 5-min 25sec mark it is all I can find right now.
Here is their linkedIn page
https://www.linkedin.com/company/sakuucorp/posts/?feedView=all
[yt]yZhKqpleAXM[/yt]

ignore me if you want, I just tell you it is not smart to do, but do whatever you want.

Thanks.

My Take On Todays Podcast Update !!!

For Those Who Haven't Figured it Out Yet; . . .Ken dropped "Two Bombshells"
in todays Podcast Update, and anyone who understands the value
of these two things, will be loading shares - starting
tomorrow morning, at the opening

Missing post # 90773, 90774, 90775 just to mention a few. What don't you want known,

Recall that the IDE Vivos submitted is for an Early Feasibility Medical Device Clinical Study (EFS). Submitting an an EFS was the FDAs recommendation to the company. The EFS Program is open to devices subject to Premarket Approval (PMA), Premarket Notification (510[k]), De Novo classification, or

https://ca.finance.yahoo.com/news/lilly-agrees-buy-us-biotech-110605998.html

And please tell me who is deleting my post here Mr moderator. Does an alternate opinion bother you or interupt your plans that much. Leads me to believe that Nebraska and Alaska are correct in their P & D theories.

Norisknorewards, That says it all. “This guy works for citadel”

The story of NWBO’s journey battling a wolfpack of market manipulators, short minions, naked shorting, spoofing orders, marking-the-closing price, frivolous lawsuits, fake journalists, fake stories, daily FUD postings, ar

Near-term strategy is a Nasdaq uplist.

CEO has always envisioned "ringing the bell" as one of his life-long goals.

Question is how quickly they get there as they already have the revenues to support an uplist.

Suddenly, there's talk of 3 rate cuts this year

3 interest rate cuts would be very good for the US and world economies. Also, very good for AVXL stock.

https://finance.yahoo.com/news/suddenly-theres-talk-3-rate-024500987.html

Good luck and GOD bless,

Was anyone here in $GDVM?

Another cybersecurity company reverse merger with near identical OS to $YCRM.

A handful of whales led by John Kent locked up the float and walked it up from sub-pennies to .13+ in 6 months.

Very retail friendly chart and almost e

Dear Zena

Good luck with your new neurologist. She sounds like a keeper….

Stay well

Foodman

Unlike their other paid promo pumps, they’ve put a muzzle on the CEO and influencers as well (for now).

I rest my case.

Neither do you, or I apparently. However, contrary to your statement, the guys on the VXIT team have been sleeping for over two years. Pandemic long gone, even with rising hospitalizations and new variants. Statements about effectiveness of a product, or launching a new website are not enough. VXIT